151 related articles for article (PubMed ID: 19940233)
1. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
Sugimoto M; Nishino M; Kodaira C; Yamade M; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
J Clin Pharmacol; 2010 Mar; 50(3):320-30. PubMed ID: 19940233
[TBL] [Abstract][Full Text] [Related]
2. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype.
Uotani T; Sugimoto M; Nishino M; Kodaira C; Yamade M; Sahara S; Yamada T; Osawa S; Sugimoto K; Tanaka T; Umemura K; Watanabe H; Miyajima H; Furuta T
Clin Gastroenterol Hepatol; 2012 Aug; 10(8):879-885.e2. PubMed ID: 22542748
[TBL] [Abstract][Full Text] [Related]
3. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.
Nishino M; Sugimoto M; Kodaira C; Yamade M; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
Dig Dis Sci; 2010 Jun; 55(6):1627-36. PubMed ID: 19672708
[TBL] [Abstract][Full Text] [Related]
4. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
Nishino M; Sugimoto M; Kodaira C; Yamade M; Uotani T; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
J Clin Pharmacol; 2011 Jul; 51(7):1079-86. PubMed ID: 20663999
[TBL] [Abstract][Full Text] [Related]
5. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes.
Hayato S; Hasegawa S; Hojo S; Okawa H; Abe H; Sugisaki N; Munesue M; Horai Y; Ohnishi A
Eur J Clin Pharmacol; 2012 May; 68(5):579-88. PubMed ID: 22108775
[TBL] [Abstract][Full Text] [Related]
6. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
7. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Sugimoto M; Nishino M; Kodaira C; Yamade M; Uotani T; Ikuma M; Furuta T
Digestion; 2012; 85(1):9-17. PubMed ID: 22122999
[TBL] [Abstract][Full Text] [Related]
8. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine.
Uotani T; Sugimoto M; Nishino M; Ichikawa H; Sahara S; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
J Clin Pharmacol; 2014 Aug; 54(8):858-64. PubMed ID: 24615745
[TBL] [Abstract][Full Text] [Related]
9. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.
Shimatani T; Moriwaki M; Xu J; Tazuma S; Inoue M
Dig Liver Dis; 2006 Nov; 38(11):802-8. PubMed ID: 16843075
[TBL] [Abstract][Full Text] [Related]
10. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype.
Sugimoto M; Shirai N; Nishino M; Kodaira C; Uotani T; Yamade M; Sahara S; Ichikawa H; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2012 Oct; 36(7):627-34. PubMed ID: 22882464
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet drugs are a risk factor for esophageal mucosal injury.
Sugimoto M; Uotani T; Nishino M; Yamade M; Sahara S; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T
Digestion; 2013; 87(4):281-9. PubMed ID: 23774797
[TBL] [Abstract][Full Text] [Related]
12. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
13. Acid-suppressive effect of rabeprazole 5 mg and 10 mg once daily by 24-hour esophageal pH monitoring in patients with non-erosive reflux disease in Japan: a multicenter, randomized, parallel-group, double-blind pharmacodynamic study.
Ashida K; Kinoshita Y; Hongo M;
Dig Dis Sci; 2011 Aug; 56(8):2333-42. PubMed ID: 21302138
[TBL] [Abstract][Full Text] [Related]
14. Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study.
Furuta K; Adachi K; Ohara S; Morita T; Tanimura T; Koshino K; Kinoshita Y
J Int Med Res; 2010; 38(4):1473-83. PubMed ID: 20926021
[TBL] [Abstract][Full Text] [Related]
15. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
Laheij RJ; Van Rossum LG; Jansen JB; Verheugt FW
Aliment Pharmacol Ther; 2003 Jul; 18(1):109-15. PubMed ID: 12848632
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic studies on PPIs: look carefully at the country of origin.
Savarino V; Savarino E; Dulbecco P
Dig Liver Dis; 2006 Nov; 38(11):808-10. PubMed ID: 16945598
[No Abstract] [Full Text] [Related]
17. A comparative study of proton-pump inhibitor tests for Chinese reflux patients in relation to the CYP2C19 genotypes.
Tseng PH; Lee YC; Chiu HM; Wang HP; Lin JT; Wu MS
J Clin Gastroenterol; 2009; 43(10):920-5. PubMed ID: 19407662
[TBL] [Abstract][Full Text] [Related]
18. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial.
Sanuki T; Fujita T; Kutsumi H; Hayakumo T; Yoshida S; Inokuchi H; Murakami M; Matsubara Y; Kuwayama H; Kawai T; Miyaji H; Fujisawa T; Terao S; Yamazaki Y; Azuma T;
J Gastroenterol; 2012 Nov; 47(11):1186-97. PubMed ID: 22526273
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
[TBL] [Abstract][Full Text] [Related]
20. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor.
Oda K; Iwakiri R; Hara M; Watanabe K; Danjo A; Shimoda R; Kikkawa A; Ootani A; Sakata H; Tsunada S; Fujimoto K
Dig Dis Sci; 2005 Oct; 50(10):1921-6. PubMed ID: 16187198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
